Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MDWD
- Price
- 16.19
- Stock movement up
- +0.84 (5.47%)
- Company name
- Mediwound Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 174.69M
- Ent value
- -
- Price/Sales
- 8.98
- Price/Book
- 5.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 22.24%
- 1 year return
- 7.93%
- 3 year return
- 4.96%
- 5 year return
- 9.56%
- 10 year return
- -10.09%
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MDWD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.98 |
| Price to Book | 5.10 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.79M |
| EPS (TTM) | -3.10 |
| FCF per share (TTM) | -2.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 19.45M |
| Gross profit (TTM) | 2.18M |
| Operating income (TTM) | -17.78M |
| Net income (TTM) | -32.62M |
| EPS (TTM) | -3.10 |
| EPS (1y forward) | -2.31 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 11.20% |
| Operating margin (TTM) | -91.45% |
| Profit margin (TTM) | -167.76% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 5.30M |
| Total current assets | 53.89M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 74.73M |
| Accounts payable | 3.13M |
| Short/Current long term debt | 6.46M |
| Total current liabilities | 25.58M |
| Total liabilities | 40.50M |
| Shareholder's equity | 34.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.45M |
| Capital expenditures (TTM) | 8.47M |
| Free cash flow (TTM) | -21.40M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -95.29% |
| Return on Assets | -43.65% |
| Return on Invested Capital | -95.29% |
| Cash Return on Invested Capital | -62.52% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.02 |
| Daily high | 16.74 |
| Daily low | 15.02 |
| Daily Volume | 116K |
| All-time high | 127.12 |
| 1y analyst estimate | 29.00 |
| Beta | 0.84 |
| EPS (TTM) | -3.10 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 27 May 2025 |
Downside potential
Loading...
Downside potential data
| MDWD | S&P500 | |
| Current price drop from All-time high | -87.26% | -10.49% |
| Highest price drop | -94.35% | -56.47% |
| Date of highest drop | 8 Sep 2023 | 9 Mar 2009 |
| Avg drop from high | -74.85% | -11.07% |
| Avg time to new high | 2782 days | 12 days |
| Max time to new high | 2781 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
174.69M
Marketcap category
Small-cap
Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Employees
100
Website
Investor relations
-
SEC filings
CEO
Sharon Malka
Country
USA
City
Yavne
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page